The N-terminal repeat domain of α-synuclein inhibits β-sheet and amyloid fibril formation

被引:111
作者
Kessler, JC
Rochet, JC
Lansbury, PT
机构
[1] Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA
[2] Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02139 USA
关键词
D O I
10.1021/bi020429y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The conversion of alpha-synuclein into amyloid fibrils in the substantia nigra is linked to Parkinson's disease. alpha-Synuclein is natively unfolded in solution, but can be induced to form either alpha-helical or beta-sheet structure depending on its concentration and the solution conditions. The N-terminus of a-synuclein comprises seven 11-amino acid repeats (XKTKEGVXXXX) which can form an amphipathic alpha-helix. Why seven repeats, rather than six or eight, survived the evolutionary process is not clear. To probe this question, two sequence variants of alpha-synuclein, one with two fewer (del2) and one with two additional (plus2) repeats, were studied. As compared to wild-type alpha-synuclein, the plus2 variant disfavors the formation of beta-sheet-rich oligomers, including amyloid fibrils. In contrast, the truncated variant, del2, favors beta-sheet and fibril formation. We propose that the repeat number in WT alpha-synuclein represents an evolutionary balance between the functional conformer of alpha-synuclein (alpha-helix and/or random coil) and its pathogenic beta-sheet conformation. N-Terminal truncation of alpha-synuclein may promote pathogenesis.
引用
收藏
页码:672 / 678
页数:7
相关论文
共 53 条
  • [1] Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system
    Abeliovich, A
    Schmitz, Y
    Fariñas, I
    Choi-Lundberg, D
    Ho, WH
    Castillo, PE
    Shinsky, N
    Verdugo, JMG
    Armanini, M
    Ryan, A
    Hynes, M
    Phillips, H
    Sulzer, D
    Rosenthal, A
    [J]. NEURON, 2000, 25 (01) : 239 - 252
  • [2] Baba M, 1998, AM J PATHOL, V152, P879
  • [3] Forcing thermodynamically unfolded proteins to fold
    Baskakov, I
    Bolen, DW
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (09) : 4831 - 4834
  • [4] Residual structure and dynamics in Parkinson's disease-associated mutants of α-synuclein
    Bussell, R
    Eliezer, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (49) : 45996 - 46003
  • [5] Neurological illness in transgenic mice expressing a prion protein with an insertional mutation
    Chiesa, R
    Piccardo, P
    Ghetti, B
    Harris, DA
    [J]. NEURON, 1998, 21 (06) : 1339 - 1351
  • [6] Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid
    Conway, KA
    Harper, JD
    Lansbury, PT
    [J]. BIOCHEMISTRY, 2000, 39 (10) : 2552 - 2563
  • [7] Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease:: Implications for pathogenesis and therapy
    Conway, KA
    Lee, SJ
    Rochet, JC
    Ding, TT
    Williamson, RE
    Lansbury, PT
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (02) : 571 - 576
  • [8] Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
    Conway, KA
    Harper, JD
    Lansbury, PT
    [J]. NATURE MEDICINE, 1998, 4 (11) : 1318 - 1320
  • [9] Synthetic filaments assembled from C-terminally truncated α-synuclein
    Crowther, RA
    Jakes, R
    Spillantini, MG
    Goedert, M
    [J]. FEBS LETTERS, 1998, 436 (03) : 309 - 312
  • [10] Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain
    Crowther, RA
    Daniel, SE
    Goedert, M
    [J]. NEUROSCIENCE LETTERS, 2000, 292 (02) : 128 - 130